Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
investigational drug |
| gptkbp:CASNumber |
1053500-13-3
|
| gptkbp:chemicalFormula |
C31H32N4O2
|
| gptkbp:clinicalTrialPhase |
gptkb:Prader-Willi_syndrome
severe obesity Phase III (terminated) |
| gptkbp:developedBy |
gptkb:Zafgen
|
| gptkbp:developmentType |
discontinued
|
| gptkbp:discontinued |
safety concerns (thromboembolic events)
|
| https://www.w3.org/2000/01/rdf-schema#label |
beloranib
|
| gptkbp:intendedUse |
treatment of obesity
|
| gptkbp:mechanismOfAction |
MetAP2 inhibitor
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2105722 |
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:UNII |
2Q1ZK1G2X9
|
| gptkbp:bfsParent |
gptkb:Zafgen
|
| gptkbp:bfsLayer |
8
|